Related Experiment Video

Updated: Jan 2, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.5K

Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients' Assessment

Radu-Stefan Miftode1, Ionela-Lăcrămioara Şerban2, Amalia-Stefana Timpau1

  • 1Department of Internal Medicine I (Cardiology), Faculty of Medicine, University of Medicine and Pharmacy "Gr. T. Popa", Iasi 700115, Romania.

Cardiology Research and Practice
|December 10, 2019
PubMed

Insights

Syndecan-1 is a promising biomarker for assessing both cardiac and liver fibrosis. This molecule

Area of Science:

  • Cardiology
  • Hepatology
  • Biomarker Discovery

Background:

  • Cardiac dysfunction in chronic liver disease is often asymptomatic, posing diagnostic challenges.
  • Syndecan-1, a transmembrane proteoglycan, is implicated in cardiac and liver fibrosis.
  • Its role in inflammation, regeneration, and lipid metabolism is increasingly recognized.

Purpose of the Study:

  • To review the mechanisms of syndecan-1's action in cardio-hepatic disorders.
  • To explore syndecan-1's potential as a dual biomarker for heart and liver conditions.
  • To highlight its diagnostic and prognostic value.

Main Methods:

  • Literature review of studies on syndecan-1 in cardiac and liver fibrosis.
  • Analysis of syndecan-1's correlation with fibrosis severity and disease activity.
  • Examination of its involvement in molecular pathways like angiotensin II activity.

Main Results:

  • Syndecan-1 levels correlate with cardiac and liver fibrosis.
  • It plays a role in atherogenesis, inflammation, and tissue repair.
  • Soluble syndecan-1 may inhibit fibrosis and influence lipid metabolism.

Conclusions:

  • Syndecan-1 shows potential as a noninvasive biomarker for both cardiac and liver fibrosis.
  • Further research is warranted to establish its clinical utility in cardio-hepatic disease management.
  • Its dual cardio-hepatic role offers new diagnostic and prognostic perspectives.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.6K
Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
624
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
405
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
626
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
397
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
181